355 related articles for article (PubMed ID: 25366565)
1. Notch signaling in serous ovarian cancer.
Groeneweg JW; Foster R; Growdon WB; Verheijen RH; Rueda BR
J Ovarian Res; 2014 Nov; 7():95. PubMed ID: 25366565
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract][Full Text] [Related]
3. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
4. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
5. The role of Notch signalling in ovarian angiogenesis.
Xie Q; Cheng Z; Chen X; Lobe CG; Liu J
J Ovarian Res; 2017 Mar; 10(1):13. PubMed ID: 28284219
[TBL] [Abstract][Full Text] [Related]
6. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
[TBL] [Abstract][Full Text] [Related]
8. Targeting notch signaling pathway in cancer: clinical development advances and challenges.
Takebe N; Nguyen D; Yang SX
Pharmacol Ther; 2014 Feb; 141(2):140-9. PubMed ID: 24076266
[TBL] [Abstract][Full Text] [Related]
9. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
Huang CC; Cheng SH; Wu CH; Li WY; Wang JS; Kung ML; Chu TH; Huang ST; Feng CT; Huang SC; Tai MH
Oncogene; 2019 Apr; 38(17):3201-3215. PubMed ID: 30626939
[TBL] [Abstract][Full Text] [Related]
10. Notch3 pathway alterations in ovarian cancer.
Hu W; Liu T; Ivan C; Sun Y; Huang J; Mangala LS; Miyake T; Dalton HJ; Pradeep S; Rupaimoole R; Previs RA; Han HD; Bottsford-Miller J; Zand B; Kang Y; Pecot CV; Nick AM; Wu SY; Lee JS; Sehgal V; Ram P; Liu J; Tucker SL; Lopez-Berestein G; Baggerly KA; Coleman RL; Sood AK
Cancer Res; 2014 Jun; 74(12):3282-93. PubMed ID: 24743243
[TBL] [Abstract][Full Text] [Related]
11. The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.
Allam H; Johnson BP; Zhang M; Lu Z; Cannon MJ; Abbott KL
J Biol Chem; 2017 Sep; 292(39):16351-16359. PubMed ID: 28842505
[TBL] [Abstract][Full Text] [Related]
12. Notch signaling: an emerging therapeutic target for cancer treatment.
Yuan X; Wu H; Xu H; Xiong H; Chu Q; Yu S; Wu GS; Wu K
Cancer Lett; 2015 Dec; 369(1):20-7. PubMed ID: 26341688
[TBL] [Abstract][Full Text] [Related]
13. Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer.
Virant-Klun I; Kenda-Suster N; Smrkolj S
J Ovarian Res; 2016 Mar; 9():12. PubMed ID: 26940129
[TBL] [Abstract][Full Text] [Related]
14. A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.
Delaney JR; Patel C; McCabe KE; Lu D; Davis MA; Tancioni I; von Schalscha T; Bartakova A; Haft C; Schlaepfer DD; Stupack DG
Oncotarget; 2015 Oct; 6(31):31104-18. PubMed ID: 26418751
[TBL] [Abstract][Full Text] [Related]
15. Targeting Notch signaling for cancer therapeutic intervention.
Shao H; Huang Q; Liu ZJ
Adv Pharmacol; 2012; 65():191-234. PubMed ID: 22959027
[TBL] [Abstract][Full Text] [Related]
16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
17. GATA1-regulated JAG1 promotes ovarian cancer progression by activating Notch signal pathway.
Liu Z; Zhu Y; Li F; Xie Y
Protoplasma; 2020 May; 257(3):901-910. PubMed ID: 31897811
[TBL] [Abstract][Full Text] [Related]
18. Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer.
Akbarzadeh M; Akbarzadeh S; Majidinia M
Pathol Res Pract; 2020 Nov; 216(11):153158. PubMed ID: 32829107
[TBL] [Abstract][Full Text] [Related]
19. Notch signaling pathway in ovarian cancer.
Rose SL
Int J Gynecol Cancer; 2009 May; 19(4):564-6. PubMed ID: 19509550
[TBL] [Abstract][Full Text] [Related]
20. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
Crane LM; Arts HJ; van Oosten M; Low PS; van der Zee AG; van Dam GM; Bart J
Cell Oncol (Dordr); 2012 Feb; 35(1):9-18. PubMed ID: 21647742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
